![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MORC2 |
Gene summary for MORC2 |
![]() |
Gene information | Species | Human | Gene symbol | MORC2 | Gene ID | 22880 |
Gene name | MORC family CW-type zinc finger 2 | |
Gene Alias | CMT2Z | |
Cytomap | 22q12.2 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q9Y6X9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
22880 | MORC2 | HCC1_Meng | Human | Liver | HCC | 3.67e-28 | 8.27e-04 | 0.0246 |
22880 | MORC2 | HCC2_Meng | Human | Liver | HCC | 1.19e-06 | 3.09e-02 | 0.0107 |
22880 | MORC2 | HCC2 | Human | Liver | HCC | 2.07e-10 | 3.34e+00 | 0.5341 |
22880 | MORC2 | S027 | Human | Liver | HCC | 2.31e-03 | 4.43e-01 | 0.2446 |
22880 | MORC2 | S028 | Human | Liver | HCC | 6.79e-04 | 3.62e-01 | 0.2503 |
22880 | MORC2 | S029 | Human | Liver | HCC | 4.06e-08 | 5.02e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
GO:001905822 | Liver | HCC | viral life cycle | 209/7958 | 317/18723 | 2.05e-17 | 2.09e-15 | 209 |
GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
GO:001907922 | Liver | HCC | viral genome replication | 94/7958 | 131/18723 | 1.02e-11 | 4.18e-10 | 94 |
GO:003304421 | Liver | HCC | regulation of chromosome organization | 125/7958 | 187/18723 | 1.35e-11 | 5.40e-10 | 125 |
GO:005079212 | Liver | HCC | regulation of viral process | 109/7958 | 164/18723 | 4.52e-10 | 1.45e-08 | 109 |
GO:190390012 | Liver | HCC | regulation of viral life cycle | 94/7958 | 148/18723 | 1.93e-07 | 3.49e-06 | 94 |
GO:004506922 | Liver | HCC | regulation of viral genome replication | 59/7958 | 85/18723 | 4.66e-07 | 7.61e-06 | 59 |
GO:200125211 | Liver | HCC | positive regulation of chromosome organization | 55/7958 | 82/18723 | 5.97e-06 | 7.35e-05 | 55 |
GO:004852511 | Liver | HCC | negative regulation of viral process | 59/7958 | 92/18723 | 2.28e-05 | 2.41e-04 | 59 |
GO:000632511 | Liver | HCC | chromatin organization | 206/7958 | 409/18723 | 7.23e-04 | 4.41e-03 | 206 |
GO:0040029 | Liver | HCC | regulation of gene expression, epigenetic | 61/7958 | 105/18723 | 9.02e-04 | 5.31e-03 | 61 |
GO:00450711 | Liver | HCC | negative regulation of viral genome replication | 35/7958 | 56/18723 | 2.00e-03 | 1.01e-02 | 35 |
GO:0039694 | Liver | HCC | viral RNA genome replication | 22/7958 | 35/18723 | 1.21e-02 | 4.41e-02 | 22 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MORC2 | SNV | Missense_Mutation | c.79G>A | p.Glu27Lys | p.E27K | Q9Y6X9 | protein_coding | deleterious(0.01) | benign(0.255) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
MORC2 | SNV | Missense_Mutation | rs780648306 | c.2128N>T | p.Pro710Ser | p.P710S | Q9Y6X9 | protein_coding | deleterious_low_confidence(0.01) | benign(0.001) | TCGA-ZJ-A8QR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MORC2 | SNV | Missense_Mutation | rs143046507 | c.1451N>A | p.Arg484His | p.R484H | Q9Y6X9 | protein_coding | tolerated(0.34) | benign(0.005) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MORC2 | SNV | Missense_Mutation | c.266N>G | p.Lys89Arg | p.K89R | Q9Y6X9 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
MORC2 | SNV | Missense_Mutation | c.79G>A | p.Glu27Lys | p.E27K | Q9Y6X9 | protein_coding | deleterious(0.01) | benign(0.255) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
MORC2 | SNV | Missense_Mutation | rs372297066 | c.2650N>A | p.Ala884Thr | p.A884T | Q9Y6X9 | protein_coding | tolerated_low_confidence(0.15) | benign(0) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MORC2 | SNV | Missense_Mutation | novel | c.485N>C | p.Val162Ala | p.V162A | Q9Y6X9 | protein_coding | tolerated(0.68) | benign(0.038) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
MORC2 | SNV | Missense_Mutation | novel | c.716N>T | p.Ser239Leu | p.S239L | Q9Y6X9 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD |
MORC2 | SNV | Missense_Mutation | rs201852637 | c.1498N>A | p.Asp500Asn | p.D500N | Q9Y6X9 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MORC2 | SNV | Missense_Mutation | rs143046507 | c.1451N>A | p.Arg484His | p.R484H | Q9Y6X9 | protein_coding | tolerated(0.34) | benign(0.005) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |